StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on the company. Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. HC Wainwright restated a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday. Finally, TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Nine investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.30 on Monday. The business has a 50-day simple moving average of $1.22 and a two-hundred day simple moving average of $1.31. The firm has a market cap of $16.66 million, a price-to-earnings ratio of -0.12 and a beta of 1.26. Marinus Pharmaceuticals has a fifty-two week low of $0.26 and a fifty-two week high of $11.26.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Point72 DIFC Ltd bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at approximately $28,000. SG Americas Securities LLC bought a new position in Marinus Pharmaceuticals in the 2nd quarter worth approximately $34,000. AQR Capital Management LLC boosted its stake in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Marinus Pharmaceuticals in the 2nd quarter worth approximately $64,000. Finally, Values First Advisors Inc. boosted its stake in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 52,257 shares during the period. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.